HTG Molecular Diagnostics (HTGMQ) Stock Statistics & Valuation Metrics

HTG Molecular Diagnostics has a market cap or net worth of $221.00. The enterprise value is ―.

HTG Molecular Diagnostics has 2,214,233 shares outstanding. The number of shares has decreased by -2.65% in one year.

HTG Molecular Diagnostics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of HTG Molecular Diagnostics is ―. HTG Molecular Diagnostics’s PEG ratio is ―.

In the last 12 months, HTG Molecular Diagnostics had revenue of 6.37M and earned -21.59M in profits. Earnings per share was -24.28.

In the last 12 months, operating cash flow was -6.39M and capital expenditures -6.24K, giving a free cash flow of -6.39M billion.

HTG Molecular Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

HTG Molecular Diagnostics upcoming earnings date is May 8, 2025, TBA Not Confirmed.

HTG Molecular Diagnostics as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, HTG Molecular Diagnostics has paid 10.84K in taxes.

HTG Molecular Diagnostics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

HTG Molecular Diagnostics has $0.00 in cash and marketable securities with $0.00 in debt, giving a net cash position of $0.00 billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for HTG Molecular Diagnostics is ―, which is 11.43% higher than the current price. The consensus rating is ―